Physician profile
Kumar Nadhan
NPI 1124514682
$9,141.10
in general payments reported to CMS, 2019-2025
24 companies · $5,929 in 2025
The $5,929 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.09 · 2020: $121 · 2021: $81.79 · 2022: $279 · 2023: $146 · 2024: $2,543 · 2025: $5,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,608 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,607.91 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.56 | 2020-2025 | |
| Incyte Corporation | $1,069.64 | 2024-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $1,016.84 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $834.82 | 2020-2025 | |
| Galderma Laboratories, L.P. | $832.78 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $773.12 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $659.05 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $470.69 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $379.55 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $276.77 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $259.00 | 2022-2025 | |
| Organon LLC | $248.74 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $243.87 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.66 | 2024-2025 | Sotyktu |
| Amgen INC. | $96.77 | 2025 | Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $58.44 | 2024 | Vtama |
| Janssen Biotech, INC. | $56.03 | 2024-2025 | Tremfya |
| Genentech USA, INC. | $55.02 | 2025 | Xolair |
| Journey Medical Corporation | $46.64 | 2025 | |
| Cipher Pharmaceuticals US LLC | $26.84 | 2025 | Spinosad, Natroba |
| Abbott Laboratories | $23.29 | 2023 | Xience Sierra |
| Janssen Pharmaceuticals, INC | $23.28 | 2020 | |
| Kerecis Limited | $19.88 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.82 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Nadhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.